TY - JOUR
T1 - Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions
AU - Nemer, Laura
AU - Krishna, Somashekar G.
AU - Shah, Zarine K.
AU - Conwell, Darwin L.
AU - Cruz-Monserrate, Zobeida
AU - Dillhoff, Mary
AU - Guttridge, Denis C.
AU - Hinton, Alice
AU - Manilchuk, Andrei
AU - Pawlik, Timothy M.
AU - Schmidt, Carl R.
AU - Talbert, Erin E.
AU - Bekaii-Saab, Tanios
AU - Hart, Phil A.
N1 - Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Objectives Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival. Methods Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models. Results Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76-2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09-2.87). Conclusions Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
AB - Objectives Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival. Methods Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models. Results Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76-2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09-2.87). Conclusions Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
KW - cachexia
KW - pancreatic cancer
KW - pancreatic enzyme replacement therapy
KW - weight loss
UR - http://www.scopus.com/inward/record.url?scp=85032627581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032627581&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000898
DO - 10.1097/MPA.0000000000000898
M3 - Article
C2 - 28902785
AN - SCOPUS:85032627581
SN - 0885-3177
VL - 46
SP - 1152
EP - 1157
JO - Pancreas
JF - Pancreas
IS - 9
ER -